Novo Nordisk Archives - DelveInsight

Novo Nordisk

Albireo's PFIC Therapy; Lupin’s Trichomoniasis Drug; Moderna's COVID vaccine; NASH Cocktail Therapy
Albireo Pharma’s PFIC Therapy; Lupin’s Trichomoniasis Oral Drug; Moderna’s Weapon Ag...

Albireo Pharma Hopeful to Commercialize its PFIC Treatment by the End of the Year Albireo Pharma, spun out of AstraZeneca, has long been working on developing potential and efficient treatment ...


pharma-news
Amylyx Raises $30M; QurAlis Announces License Agreement Deal With Lilly; COVID-19 Vaccine Update...

Amylyx Pharmaceuticals grabs USD 30 Million  Amylyx Pharmaceuticals has grabbed USD 30 million boosts after posting positive data, which showed it could help decrease amyotrophic lateral s...


Pharma news
Nordisk ties up with Dicerna; Pfizer’s drug gets FDA nod

Novo Nordisk has announced to enter into a collaboration with Dicerna’s RNAi platform to focus on metabolic and liver-related diseases. The companies will be focusing to advance the treatment ...


NOTIZIA
Notizia

A Praluent boost for Sanofi, and Regeneron The U.S. FDA has given its nod to Praluent (alirocumab) to be used for reducing the risk of heart attack, stroke, and unstable angina requiring hospit...


NASH
Notizia

FDA gives thumbs-up to Balversa The U.S. FDA has granted approval of Balversa (erdafitinib) to Belgium-based Janssen Pharmaceutica, for the treatment of advanced or metastatic bladder cancer. T...


Peloton Therapeutics
Peloton raises $150M; BiomX raises $32M; Abbott and Novo collaborate; Blaze Bioscience nets $5M

Peloton Therapeutics raises USD 150 Million for treating Advance Kidney Cancer Peloton Therapeutics has been in the process of developing small molecule drugs to treat Cancer, has raised&...


Oncology
Notizia

Stopping breast cancer metastasis by killing tumor cells in their sleep Oncology researchers believed that dormant breast cancer cells are not responsive to chemotherapy. But these inactive can...


patent ductus arteriosus
Notizia

Axovant tips nelotanserin from small molecule R&D Axovant has stopped nelotanserin development after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia. The d...


Novo Nordisk
Snippet

Novo Nordisk set to restructure R&D business Novo Nordisk, Danish drug maker, declared its plans to reorganise their R&D business, which include lay-off 400 workers of operations in Denmar...


astellas
Commercial

NICE Rejects Gilead Sciences’ Yescarta on Cost Concerns The United Kingdom’s government-funded health service isn’t being so nice to Gilead Sciences’ CAR-T blood cancer treatment Yescar...


Editor's Pick
22 Healthcare Trends & Innovations to Watch in 2022 and Beyond

With the advent of new-age healthcare industry trends that are evident as of now, there...

Assessment of Key Products that Got FDA Approval in Second Half (H2) of 2021

Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did...

Analyzing the Key Trends Driving the Biosimilar Market Growth

The Biosimilars market is growing at a breakneck pace. The biosimilar market provides a...

CAR-T Cell Therapy aka Miraculous Technology: Mapping the Market, Approved Th...

Chimeric antigen receptor T-cell (CAR T) therapies are shown to have transformative pot...

Myelodysplastic Syndromes (MDS): Key Pharma Players Unveiling Updated Finding...

There has been limited progress in the approval of novel agents in MDS. It has been a l...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.